Replies to post #110621 on Biotech Values

[masterlongevity]

this is addressed in Roche's slideset. THe PPMS population is very heterogenous. They did a post-hoc on the Rituxan data and there were some groups who responded much more favorably. they will be going after a more defined PPMS group with Ocrelizumab